Nathalie Y. Rosin

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Jan A. Burger, Michael J. Keating, William G. Wierda et al. · The Lancet Oncology · 2014 · 330 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Julia Hoellenriegel, Dirk Zboralski, Christian Maasch et al. · Blood · 2013 · 229 citations · Full text

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

Kumudha Balakrishnan, Marisa Peluso, Min Fu et al. · Leukemia · 2015 · 165 citations · Full text

Signal Transduction, Signaling Pathway, Pi3k/akt/s6 Pathway +11

Genotypic and phenotypic characterization of Pseudomonas aeruginosa isolates from urinary tract infections

Petra Tielen, Maike Narten, Nathalie Y. Rosin et al. · International Journal of Medical Microbiology · 2010 · 63 citations

Urinary Tract Infections, Gram-negative Bacteriology, Pathogenic Microbiology +9

Susceptibility of Pseudomonas aeruginosa Urinary Tract Isolates and Influence of Urinary Tract Conditions on Antibiotic Tolerance

Maike Narten, Nathalie Y. Rosin, Max Schobert et al. · Current Microbiology · 2011 · 48 citations

Antimicrobial Resistance Gene, Antibiotic Tolerance, Antimicrobial Susceptibility +9